Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

248
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
248
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

137
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
137
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

157
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

191
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
191
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

337
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
337
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Auto-segmentation of organs-of-interest clinical acceptability & reproducibility framework in head and neck cancer.

Physics and imaging in radiation oncology·2026
Same author

Making head and neck cancer clinical data Findable-Accessible-Interoperable-Reusable to support multi-institutional collaboration and federated learning.

BJR artificial intelligence·2026
Same author

A practical framework for operationalising responsible and equitable artificial intelligence in health care: tackling bias, inequity, and implementation challenges.

The Lancet. Digital health·2026
Same author

Evaluation of ensilication technology for ambient DNA preservation.

NAR molecular medicine·2026
Same author

Identification of a Cytokine Biomarker for Prognostic Modeling of Breast Cancer-Related Lymphedema.

Cancer research communications·2026
Same author

Discovery of predictive biomarkers for cancer therapy through computational approaches.

Nature reviews. Clinical oncology·2026

関連する実験動画

Updated: Apr 29, 2026

Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

41.3K

大規模な薬剤ゲノミクス研究における矛盾

Benjamin Haibe-Kains1, Nehme El-Hachem2, Nicolai Juul Birkbak3

  • 11] Institut de Recherches Cliniques de Montréal, University of Montreal, Montreal, Quebec, Canada [2] Ontario Cancer Institute, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario M5G 2M9, Canada.

Nature
|November 29, 2013
PubMed
まとめ

2つの製薬遺伝学研究は,類似したゲノムデータを示したが,非常に不一致な薬物反応データを示した. この矛盾は,遺伝子と薬物の関連性を評価し,がん薬の選択に懸念を喚起しています.

さらに関連する動画

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

9.2K
Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization
08:27

Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization

Published on: July 27, 2021

4.6K

関連する実験動画

Last Updated: Apr 29, 2026

Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

41.3K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

9.2K
Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization
08:27

Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization

Published on: July 27, 2021

4.6K

科学分野:

  • ファルマコゲノミクスとは
  • 遺伝学 遺伝学とは
  • ドラッグ・ディスカバリー・ディスカバリー・ドラッグ・ディスカバリー・ドラッグ・ディスカバリー

背景:

  • 最近の大規模な製薬遺伝学研究は,薬剤反応を理解するために貴重なデータを提供しています.
  • 研究におけるゲノムデータの一貫性は,信頼性の高い研究に不可欠です.
  • 薬剤反応の変動性は,薬剤ゲノミクス研究における課題です.

研究 の 目的:

  • ゲノムデータと薬剤反応の測定を2つの大規模製薬ゲノミクス研究で比較する.
  • 薬物反応データにおける不一致の潜在的な理由を特定する.
  • データの不一致が将来の薬剤ゲノミクス研究と薬剤開発に及ぼす影響を評価する.

主な方法:

  • 2つの独立した研究からのゲノムデータセットの比較分析.
  • 2つの研究で報告された薬物反応測定値の分析.
  • 潜在的変動源を特定するための文献レビュー.

主要な成果:

  • ゲノムデータは2つの研究間で高度に相関していました.
  • 薬剤反応データは,研究間の有意な不一致を示した.
  • 薬剤への反応における観察された不一致の源は,未定のままである.

結論:

  • 一貫したゲノムデータにもかかわらず,薬剤反応の測定の不一致は課題をもたらします.
  • 不一致は,遺伝子薬物関連の評価に影響を与える可能性があります.
  • 矛盾を解消し,臨床応用と薬剤選択のための薬剤ゲノミクスデータの信頼性を確保するために,さらなる調査が必要である.